95 related articles for article (PubMed ID: 11843938)
1. Costs and benefits of cervical screening IV: valuation by women of the cervical screening programme.
Wordsworth S; Ryan M; Waugh N
Cytopathology; 2001 Dec; 12(6):367-76. PubMed ID: 11843938
[TBL] [Abstract][Full Text] [Related]
2. Costs and benefits of cervical screening. III. Cost/benefit analysis of a call of previously unscreened women.
Waugh N; Smith I; Robertson A; Reid GS; Halkerston R; Grant A
Cytopathology; 1996 Aug; 7(4):249-55. PubMed ID: 8853971
[TBL] [Abstract][Full Text] [Related]
3. Costs and benefits of cervical screening. I. The costs of the cervical screening programme.
Waugh N; Smith I; Robertson A; Reid GS; Halkerston R; Grant A
Cytopathology; 1996 Aug; 7(4):231-40. PubMed ID: 8853969
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
[TBL] [Abstract][Full Text] [Related]
5. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.
Goldie SJ; Weinstein MC; Kuntz KM; Freedberg KA
Ann Intern Med; 1999 Jan; 130(2):97-107. PubMed ID: 10068381
[TBL] [Abstract][Full Text] [Related]
6. Willingness to pay for new Papanicolaou test technologies.
Raab SS; Grzybicki DM; Hart AR; Kiely S; Andrew-JaJa C; Scioscia E
Am J Clin Pathol; 2002 Apr; 117(4):524-33. PubMed ID: 11939725
[TBL] [Abstract][Full Text] [Related]
7. Costs and benefits of cervical screening. II. Is it worthwhile reducing the screening interval from 5 to 3 years?
Waugh N; Robertson A
Cytopathology; 1996 Aug; 7(4):241-8. PubMed ID: 8853970
[TBL] [Abstract][Full Text] [Related]
8. An examination of the role of opportunistic smear taking in the NHS cervical screening programme using data from the CSEU cervical screening cohort study.
Blanks RG; Moss SM; Coleman DA; Swerdlow AJ
BJOG; 2007 Nov; 114(11):1408-13. PubMed ID: 17803716
[TBL] [Abstract][Full Text] [Related]
9. Cost-effective policies for cervical cancer screening. An international review.
Fahs MC; Plichta SB; Mandelblatt JS
Pharmacoeconomics; 1996 Mar; 9(3):211-30. PubMed ID: 10160098
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of the conventional papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors.
Taylor LA; Sorensen SV; Ray NF; Halpern MT; Harper DM
Arch Fam Med; 2000 Aug; 9(8):713-21. PubMed ID: 10927709
[TBL] [Abstract][Full Text] [Related]
11. [Costs of population cervical cancer screening program in Poland between 2007-2009].
Spaczyński M; Karowicz-Bilinska A; Kedzia W; Molińska-Glura M; Seroczyński P; Januszek-Michalecka L; Rokita W; Nowak-Markwitz E
Ginekol Pol; 2010 Oct; 81(10):750-6. PubMed ID: 21117303
[TBL] [Abstract][Full Text] [Related]
12. Management of women with abnormal cervical cytology: treatment patterns and associated costs in England and Wales.
Martin-Hirsch P; Rash B; Martin A; Standaert B
BJOG; 2007 Apr; 114(4):408-15. PubMed ID: 17378815
[TBL] [Abstract][Full Text] [Related]
13. Prevention of cervical cancer with screening programme in Branicevo District and cost-effectiveness analysis adjusted to the territory of the Republic of Serbia.
Perovic S
J BUON; 2009; 14(1):93-6. PubMed ID: 19373953
[TBL] [Abstract][Full Text] [Related]
14. Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia.
Ezat SW; Aljunid S
Asian Pac J Cancer Prev; 2010; 11(4):943-51. PubMed ID: 21133606
[TBL] [Abstract][Full Text] [Related]
15. Economic aspects of screening for cervical cancer in New Zealand.
Bethwaite J; Rayner T; Bethwaite P
N Z Med J; 1986 Oct; 99(811):747-51. PubMed ID: 3464889
[TBL] [Abstract][Full Text] [Related]
16. Cervical cancer screening program of Paraná: cost-effective model in a developing country.
Bleggi Torres LF; Werner B; Totsugui J; Collaço LM; Araújo SR; Huçulak M; Boza EJ; Fischer RM; De Laat L; Sobbania LC; Raggio A
Diagn Cytopathol; 2003 Jul; 29(1):49-54. PubMed ID: 12827718
[TBL] [Abstract][Full Text] [Related]
17. [Cancer of the cervix uteri: analysis of the cost-benefit and efficacy of opportunistic screening versus organized screening].
Castronovo V; Foidart JM; Boniver J
Rev Med Liege; 1998 May; 53(5):305-7. PubMed ID: 9689888
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of cervical cancer screening for the elderly.
Fahs MC; Mandelblatt J; Schechter C; Muller C
Ann Intern Med; 1992 Sep; 117(6):520-7. PubMed ID: 1503355
[TBL] [Abstract][Full Text] [Related]
19. Cervical screening interval: costing the options in one health authority.
Grant CM
J Public Health Med; 1999 Jun; 21(2):140-4. PubMed ID: 10432241
[TBL] [Abstract][Full Text] [Related]
20. [Cost effectiveness analysis of screening strategies for cervical cancer in Tunisia].
Lazaar HB; Aounallah-Skhiri H; Oueslati F; Frikha H; Achour N; Hsairi M
East Mediterr Health J; 2010 Jun; 16(6):602-8. PubMed ID: 20799586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
